广痛消泡沫气雾剂治疗慢性肛裂的疗效观察和机制研究
|
摘要
1目的
近年来慢性肛裂的研究有了新的进展。首先对传统的药物和术式深入的研究得到更多更可靠更翔实的数据,为临床决策提供了有利的证据支持；其次一些新的药物如膝钩藻毒素、磷酸二酯酶抑制剂、左旋精氨酸、毒蕈碱激动剂和血管紧张素转化酶抑制剂等正在研究中；与此同时对传统术式的改进和创新也在不断进行中。虽然传统的药物治疗费用较低,但疗程较长、治愈率不高、副作用频发以及远期复发率较高等导致患者对这些药物治疗依从性较差,手术疗法虽治愈率高,却有一定的大便失禁风险,治疗费用也较高。
我们的前期研究表明广痛消泡沫气雾剂对各种肛肠疾病有较好的止痛解痉作用,此外还有一定的抗炎止血和促愈合作用。本研究的目的在于观察广痛消泡沫气雾剂治疗慢性肛裂的疗效,并从缓解肛门内括约肌痉挛和抑制炎性痛痛觉敏化两个角度研究该药的作用机制。
2方法
本研究分为三部分。第一部分为文献研究,通过回顾广痛消泡沫气雾剂的前期研究基础和国内外慢性肛裂以及痛觉敏化分子生物学的研究进展,我们希望从中找到研究广痛消泡沫气雾剂治疗肛裂机制的一些切入点。第二部分为广痛消泡沫气雾剂临床疗效观察。我们采用随机对照方法从治愈率、缓解疼痛、降低肛管静息压和改善生活质量等角度比较了广痛消泡沫气雾剂和硝酸甘油软膏的疗效,并在治疗和随访过程中密切关注治疗可能带来的副作用和远期复发率。第三部分为广痛消泡沫气雾剂的动物实验研究。实验一通过观察大鼠疼痛行为学、局部组织病理和排便改变三个角度论证大鼠肛裂模型的可行性；实验二从疼痛行为学角度比较了各药物对大鼠肛裂疼痛的疗效；实验三采用硝酸还原酶法检测肛裂裂口局部组织NO浓度,研究广痛消泡沫气雾剂与内括约肌重要的舒张递质的关系；实验四采用酶联免疫分析法检测大鼠血清中PGE2的浓度,研究广痛消泡沫气雾剂与炎症因子PGE2的关系；实验五采用免疫组织化学方法检测大鼠脊髓NR2B的表达,研究广痛消泡沫气雾剂对炎性痛痛觉敏化中的重要受体表达的影响。
3结果
3.1临床研究
(1)总疗效：广痛消泡沫气雾剂治疗慢性肛裂的治愈率为56.25%,硝酸甘油软膏(GTN)治愈率为51.61%,两者无显著差异(p=0.5838)
(2)肛管静息压：两组治疗前后比较都有显著下降(p=0.0138,p=0.0154)；但治疗后两组间无显著差异(p=0.6843)
(3)疼痛积分：治疗结束后两组间无显著差异(p=0.5654),但两组治疗前后比较都有显著下降(p=0.0011,p=0.0038)；治疗第7天两组疼痛较治疗前均有显著缓解(p=0.0231,p=0.0386),治疗组优于对照组(p=0.0176)；治疗第14天与第7天比较两组均有显著缓解(p=0.0178,p=0.0255),治疗组疼痛积分亦低于对照组(p=0.0148)；治疗第21天与第14天比较两组均有显著缓解(p=0.0258,p=0.0169),治疗组疼痛积分亦低于对照组(p=0.0315)；从治疗第28天开始(第28天、35天和42天)治疗组疼痛积分未有明显下降(p=0.3265,p=0.5284,p=0.5324),但对照组仍缓慢下降(p=0.0232,p=0.0154,p=0.0373)；虽然如此治疗第28天和35天,治疗组疼痛积分仍明显低于对照组(p=0.0139,p=0.0468),第42天也就是治疗结束时两组疼痛积分无显著差异(p=0.5654)
(4)生活质量：①躯体疼痛：两组治疗前后比较都有显著下降(p=0.0159,p=0.0278),治疗后两组间比较无显著差异(p=0.8621)；②生理职能：两组治疗前后比较都有显著下降(p=0.0306,p=0.0351),治疗后两组间比较无显著差异(p=0.9781)；③精力：两组治疗前后比较都有显著下降(p=0.0387,p=0.0405),治疗后两组间比较无显著差异(p=0.2572)；④两组患者生理机能、一般健康状况、社会功能、情感职能以及精神健康方面治疗前后均无显著改变(p均大于0.05)。
(5)治疗组疗效与相关因素关系：治疗组疗效与患者病程长短和肛裂分期有关(p=0.0079,p=0.0168),与患者性别和年龄无明显关系(p=0.9730,p=0.3295)
(6)副作用：对照组有7名患者(20%)出现轻度头痛,其中3名患者因头痛频发退出本研究。治疗组治疗过程中未见明显副作用,两者差异显著(p=0.0112)
(7)复发率：虽然对照组(29.41%)复发率高于治疗组(11.11%),但无统计学意义(p=0.2285)。
3.2实验研究
(1)疼痛行为学检查
机械性收缩反射阈值：小剂量广痛消组治疗后阈值无明显改变(p=0.4059)；中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组治疗后阈值均明显升高(p=0.0346,0.0105,p=0.0226,p=0.0188)；末次给药后1h,中剂量广痛消组、硝酸甘油软膏组和吲哚美辛组之间无显著差异(p均大于0.05)；大剂量广痛消组机械性收缩反射阈值明显高于吲哚美辛组(p=0.0454)。
热退缩潜伏期：治疗后小剂量广痛消组热退缩潜伏期无明显改变(p=0.1558),中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组治疗后热退缩潜伏期均明显延长(p=0.0231,p=0.0117,p=0.0265,p=0.0185)；末次给药后1h,中剂量广痛消组、硝酸甘油软膏组和吲哚美辛组之间无显著差异(p均大于0.05)；大剂量广痛消组末次给药后1h热退缩潜伏期明显长于吲哚美辛组(p=0.0433)。
(2)裂口局部组织NO浓度
小剂量广痛消组、中剂量广痛消组和吲哚美辛组与模型组相比则无显著差异(p=0.3073,p=0.1734,p=0.3317)；GTN组和大剂量广痛消组浓度明显高于模型组(p=0.0121,0.0287),GTN组亦明显高于大剂量广痛消组(p=0.0108)。
(3)血清PGE2的浓度值
小剂量广痛消组、中剂量广痛消组和GTN组与模型组相比则无显著差异(p=0.7760,p=0.0869,p=0.7053)；吲哚美辛组和大剂量广痛消泡沫气雾剂组PGE2浓度明显低于模型组(p=0.0023,p=0.0415),吲哚美辛组亦明显低于大剂量广痛消组(p=0.0410)。
(4)脊髓NR2B阳性神经元细胞数
小剂量广痛消组与模型组相比无显著差异(p=0.6563)；中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组阳性神经元细胞数明显少于模型组(p=0.0496,p=0.0125,p=0.0465,p=0.0242)；大剂量广痛消组阳性神经元细胞数明显少于吲哚美辛组(p=0.0128),中剂量广痛消组阳性神经元细胞数与吲哚美辛组无显著差异(p=0.0997),GTN组阳性神经元数目明显多于吲哚美辛组(p=0.0454)。
4结论
广痛消泡沫气雾剂和硝酸甘油软膏用于治疗慢性肛裂时都能显著缓解慢性肛裂患者的疼痛,降低肛管静息压,改善患者生活质量(躯体疼痛、生理职能和精力),两者治愈率无显著差异。但是广痛消泡沫气雾剂具有止痛速度更快和疗程更短的优势。此外广痛消泡沫气雾剂治疗过程中未见明显副作用。疗效与相关因素分析显示,广痛消对于病程较短者疗效较佳,治疗Ⅱ期肛裂疗效优于Ⅲ期肛裂。
广痛消泡沫气雾剂治疗肛裂的机制可能有：通过提高肛门内括约肌局部NO浓度缓解括约肌痉挛；通过抑制炎性因子PGE2生成和脊髓背角NR2B的表达抑制炎性痛痛觉敏化,而且上述作用有一定的量效关系,剂量越大,作用越明显。
1 Objectives
Studies of chronic anal fissure have made new progress in recent years. Firstly, the studies of the traditional drugs and classic operations have obtained more reliable datas, which will provide favorable evidence to support clinical decision-making; secondly, Some new drugs such as Gonyautoxin, phosphodiesterase inhibitor, L-arginine and muscarinic agonists and angiotensin-converting enzyme inhibitors are being researched; and the improvements to the traditional operations and bold innovations of the new operations are ongoing at the same time. Although the traditional medication treatments have lower cost, the cure rate of them are not high, meanwhile the side effects and long-term recurrence rate are high, so the compliance of patients to these treatments are not very good. Al though the cure rate of surgical therapies are relatively high, there are a certain risks of fecal incontinence, and the treatment cost is also higher.
Our previous studies have showed that the Guangtongxiao foam aerosol (GTX) has significant effects on pain relieving and spasmolysis in addition to certain effects of anti-inflammatory hemostatic and wound healing on a variety of anorectal diseases. The objectives of this subject are to observe the efficacy of GTX in the treatment of chronic anal fissure, and to study its mechanism of action from relieving the internal anal sphincter spasm and inhibition to the hyperalgesia of inflammatory pain.
2 Methods
This study consists of three parts. The first part is the literature research by reviewing the previous studies of GTX and the progress of treatment of chronic anal fissure and hyperalgesia research in molecular biology. We hope to find research targets in the study of mechanisms of GTX in the treatment of chronic anal fissure. The second part is the clinical efficacy research of GTX. We adopted randomized controlled approach to compare the efficacy of GTX and GTN from cure rate, pain relieving, reducing of anal resting pressure and improving to the quality of life, meanwhile we paid close attention to the side effects and and long-term recurrence rate of both drugs during the treatment and the follow-up. The third part is about the animal studies of GTX. We demonstrated the feasibility of the model of chronic anal fissure in rats by the observation of pain behaviors, pathology and bowel movement of the rats before and after the molding in experiment one; we compared the efficacy of various drugs in rats with chronic anal fissure from the perspective of pain behaviors in the second experiment; we adopted the nitrate reductase method to measure the concentration of NO in experiment three, to study the relation between GTX and the important neurotransmitter of internal anal sphincter; we adopted enzyme linked immunosorbent assay to measure concentration of PGE2 in serum in experiment four to study the relation between GTX and PGE2which is an important inflammatory factor; We adopted immunohistochemistry to detect NR2B expression in the spinal cord of rats to study the impact of GTX on the important receptor of hyperalgesia in experiment five.
3 Results
3.1 clinical research
(1)the cure rate:The cure rate of GTX was 56.25%, while the cure rate of glyceryl trinitrate ointment (GTN) was 51.61%, and there was no significant difference between them(p=0.5838);
(2)anal resting pressure:The anal resting pressures of both groups decreased significantly after the treatment (both p were less than 0.0001); and there was no significant difference between the two groups after the treatment (p=0.6843);
(3) pain scores:Pain of both groups alleviated significantly after the treatment(p=0.0011, p=0.0038), but there was no significant difference (p=0.5654) between the two groups after the treatment; pain of both groups alleviated significantly (p=0.0231, p=0.0386) at the 7th day of the treatment, and the treatment group alleviated more significantly than the control group (p=0.0176); pain of both groups alleviated significantly (p=0.0178, p=0.0255) at the 14th day than those of the 7th day, and the treatment group alleviated more significantly than the control group (p=0.0148); pain of both groups alleviated significantly (p=0.0258, p=0.0169) at the 21th day than those of the 14th day, and the treatment group alleviated more significantly than the control group (p=0.0315); pain scores of the treatment group did not decreased significantly ever since the 28th day of the treatment(p=0.3265, p=0.5284, p=0.5324), but the control group decreased all the time until the end of the treatment (p=0.0232, p=0.0154, p=0.0373); but the pain scores of the treatment group were still significantly lower than those of the control group (p=0.0139, p=0.0468), no significant difference existed between the two groups at the 42th day of the treatment (p=0.5654).
(4) quality of life:①bodily pain:both groups decreased significantly (p=0.0159, p=0.0278) after the treatment, but no significant difference(p=0.8621)existed between the two groups after the treatment;②role physical:both groups decreased significantly (p=0.0306, p=0.0351)after the treatment, but no significant difference (p=0.9781)existed between the two groups after the treatment;③vitality:both groups decreased significantly (p=0.0387, p=0.0405) after the treatment, but no significant difference (p=0.2572) existed between the two groups after the treatment; (4) there was no significant change about the physical functioning, general health, social functioning, role emotional and mental health (all p were greater than 0.05).
(5)Analysis to the relationship between efficacy of the treatment group and relevant factors:efficacy of the treatment group had relationship with duration of disease and anal fissure stage (p=0.0079, p=0.0168); no significant relationship was observed between efficacy and gender/age (p=0.9730, p=0.3295).
(6)side effects:seven patients in the control group (20%) had mild headache in the course of treatment, and three of them withdrew from the study because of headache-prone. There was no significant side effects in the treatment group in the course of treatment, significant difference existed between them(p=0.0112).
(7)relapse rate:the relapse rate of the control group (29.41%) was higher than that of the treatment group (11.11%)in the follow-up,but no statistical significance existed between them(p=0.2285).
3.2 zoopery research
(1)pain behavior tests
MWT:MWT of the low-dose group of GTX did not change significantly (p=0.4059) after the treatment; MWT of the middle-dose group of GTX, large-dose group of GTX, GTN group and the indomethacin group rised significantly (p=0.0346, 0.0105, p=0.0226, p=0.0188)at the end of the treatment; there was no significant difference among the middle-dose group of GTX, GTN group and the indomethacin group (all p were greater than 0.05); MWT of the large-dose group of GTX was significantly higher than that of the indomethacin group (p=0.0454).
TWL:TWL of the low-dose group of GTX didn't change significantly (p=0.1558) after the treatment; TWL of the middle-dose group of GTX, large-dose group of GTX, GTN group and the indomethacin group rised significantly (p=0.0231, p=0.0117, p=0.0265, p=0.0185) at the end of the treatment; there was no significant difference among the middle-dose group of GTX, GTN group and the indomethacin group (all p were greater than 0.05); TWL of the large-dose group of GTX was significantly higher than that of the indomethacin group (p=0.0433).
(2)concentration of NO in the local organization The concentration of NO of the low-dose group of GTX, middle-dose group of GTX and the indomethacin group were not significantly different with model group (p=0.3073, p=0.1734, p=0.3317); but that of GTN group was significantly higher than those of the model group (p=0.0121) and large-dose group of GTX (p=0.0108).
(3)serum concentration of PGE2 The serum concentration of PGE2 of the low-dose group of GTX, middle-dose group of GTX and the GTN group were not significantly different from model group (p=0.7760, p=0.0869, p=0.7053); but that of indomethacin group was significantly higher than those of the model group (p=0.0023) and large-dose group of GTX (p=0.0410).
(4)numbers of NR2B positive neurons in the spinal cord There was no significant difference between the low-dose group of GTX and the model group (p=0.6563); and the numbers of NR2B positive neurons of the middle-dose group of GTX, the large-dose group of GTX, the GTN group and the indomethacin group were all less than the model group remarkably (p=0.0496, p=0.0125, p=0.0465, p=0.0242); the number of NR2B positive neurons of the large-dose group of GTX was less than the indomethacin group remarkably(p=0.0128); there was no significant difference between the middle-dose group of GTX and the indomethacin group (p=0.0997); and the number of NR2B positive neurons of the GTN group was more than the indomethacin group (p=0.0454).
4 Conclusions
GTX and GTN could both relieve the pain of patients, reduce anal resting pressure, and improve patients'quality of life (bodily pain, role physical and vitality) significantly in treating patients with chronic anal fissure, no significant differences were observed in the cure rate. But GTX could relieve the pain more quickly and cured the chronic anal fissure in shorter course of treatment. Besides, no significant side effects were observed in the research. The analysis between efficacy and correlative factors showed that the shorter course of disease the better efficacy, and GTX was more effective in treating stageⅡanal fissure than stage III anal fissure.
The mechanism of GTX in treating chronic anal fissure were:to alleviate sphincter spasm by increasing the local NO concentration in the internal anal sphincter; to inhibit inflammatory hyperalgesia by inhibiting the expression of inflammatory factors--PGE2 in the serum and the expression of NR2B in the spinal cord dorsal horn, and the greater the dose, the more obvious efficacy.
近年来慢性肛裂的研究有了新的进展。首先对传统的药物和术式深入的研究得到更多更可靠更翔实的数据,为临床决策提供了有利的证据支持；其次一些新的药物如膝钩藻毒素、磷酸二酯酶抑制剂、左旋精氨酸、毒蕈碱激动剂和血管紧张素转化酶抑制剂等正在研究中；与此同时对传统术式的改进和创新也在不断进行中。虽然传统的药物治疗费用较低,但疗程较长、治愈率不高、副作用频发以及远期复发率较高等导致患者对这些药物治疗依从性较差,手术疗法虽治愈率高,却有一定的大便失禁风险,治疗费用也较高。
我们的前期研究表明广痛消泡沫气雾剂对各种肛肠疾病有较好的止痛解痉作用,此外还有一定的抗炎止血和促愈合作用。本研究的目的在于观察广痛消泡沫气雾剂治疗慢性肛裂的疗效,并从缓解肛门内括约肌痉挛和抑制炎性痛痛觉敏化两个角度研究该药的作用机制。
2方法
本研究分为三部分。第一部分为文献研究,通过回顾广痛消泡沫气雾剂的前期研究基础和国内外慢性肛裂以及痛觉敏化分子生物学的研究进展,我们希望从中找到研究广痛消泡沫气雾剂治疗肛裂机制的一些切入点。第二部分为广痛消泡沫气雾剂临床疗效观察。我们采用随机对照方法从治愈率、缓解疼痛、降低肛管静息压和改善生活质量等角度比较了广痛消泡沫气雾剂和硝酸甘油软膏的疗效,并在治疗和随访过程中密切关注治疗可能带来的副作用和远期复发率。第三部分为广痛消泡沫气雾剂的动物实验研究。实验一通过观察大鼠疼痛行为学、局部组织病理和排便改变三个角度论证大鼠肛裂模型的可行性；实验二从疼痛行为学角度比较了各药物对大鼠肛裂疼痛的疗效；实验三采用硝酸还原酶法检测肛裂裂口局部组织NO浓度,研究广痛消泡沫气雾剂与内括约肌重要的舒张递质的关系；实验四采用酶联免疫分析法检测大鼠血清中PGE2的浓度,研究广痛消泡沫气雾剂与炎症因子PGE2的关系；实验五采用免疫组织化学方法检测大鼠脊髓NR2B的表达,研究广痛消泡沫气雾剂对炎性痛痛觉敏化中的重要受体表达的影响。
3结果
3.1临床研究
(1)总疗效：广痛消泡沫气雾剂治疗慢性肛裂的治愈率为56.25%,硝酸甘油软膏(GTN)治愈率为51.61%,两者无显著差异(p=0.5838)
(2)肛管静息压：两组治疗前后比较都有显著下降(p=0.0138,p=0.0154)；但治疗后两组间无显著差异(p=0.6843)
(3)疼痛积分：治疗结束后两组间无显著差异(p=0.5654),但两组治疗前后比较都有显著下降(p=0.0011,p=0.0038)；治疗第7天两组疼痛较治疗前均有显著缓解(p=0.0231,p=0.0386),治疗组优于对照组(p=0.0176)；治疗第14天与第7天比较两组均有显著缓解(p=0.0178,p=0.0255),治疗组疼痛积分亦低于对照组(p=0.0148)；治疗第21天与第14天比较两组均有显著缓解(p=0.0258,p=0.0169),治疗组疼痛积分亦低于对照组(p=0.0315)；从治疗第28天开始(第28天、35天和42天)治疗组疼痛积分未有明显下降(p=0.3265,p=0.5284,p=0.5324),但对照组仍缓慢下降(p=0.0232,p=0.0154,p=0.0373)；虽然如此治疗第28天和35天,治疗组疼痛积分仍明显低于对照组(p=0.0139,p=0.0468),第42天也就是治疗结束时两组疼痛积分无显著差异(p=0.5654)
(4)生活质量：①躯体疼痛：两组治疗前后比较都有显著下降(p=0.0159,p=0.0278),治疗后两组间比较无显著差异(p=0.8621)；②生理职能：两组治疗前后比较都有显著下降(p=0.0306,p=0.0351),治疗后两组间比较无显著差异(p=0.9781)；③精力：两组治疗前后比较都有显著下降(p=0.0387,p=0.0405),治疗后两组间比较无显著差异(p=0.2572)；④两组患者生理机能、一般健康状况、社会功能、情感职能以及精神健康方面治疗前后均无显著改变(p均大于0.05)。
(5)治疗组疗效与相关因素关系：治疗组疗效与患者病程长短和肛裂分期有关(p=0.0079,p=0.0168),与患者性别和年龄无明显关系(p=0.9730,p=0.3295)
(6)副作用：对照组有7名患者(20%)出现轻度头痛,其中3名患者因头痛频发退出本研究。治疗组治疗过程中未见明显副作用,两者差异显著(p=0.0112)
(7)复发率：虽然对照组(29.41%)复发率高于治疗组(11.11%),但无统计学意义(p=0.2285)。
3.2实验研究
(1)疼痛行为学检查
机械性收缩反射阈值：小剂量广痛消组治疗后阈值无明显改变(p=0.4059)；中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组治疗后阈值均明显升高(p=0.0346,0.0105,p=0.0226,p=0.0188)；末次给药后1h,中剂量广痛消组、硝酸甘油软膏组和吲哚美辛组之间无显著差异(p均大于0.05)；大剂量广痛消组机械性收缩反射阈值明显高于吲哚美辛组(p=0.0454)。
热退缩潜伏期：治疗后小剂量广痛消组热退缩潜伏期无明显改变(p=0.1558),中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组治疗后热退缩潜伏期均明显延长(p=0.0231,p=0.0117,p=0.0265,p=0.0185)；末次给药后1h,中剂量广痛消组、硝酸甘油软膏组和吲哚美辛组之间无显著差异(p均大于0.05)；大剂量广痛消组末次给药后1h热退缩潜伏期明显长于吲哚美辛组(p=0.0433)。
(2)裂口局部组织NO浓度
小剂量广痛消组、中剂量广痛消组和吲哚美辛组与模型组相比则无显著差异(p=0.3073,p=0.1734,p=0.3317)；GTN组和大剂量广痛消组浓度明显高于模型组(p=0.0121,0.0287),GTN组亦明显高于大剂量广痛消组(p=0.0108)。
(3)血清PGE2的浓度值
小剂量广痛消组、中剂量广痛消组和GTN组与模型组相比则无显著差异(p=0.7760,p=0.0869,p=0.7053)；吲哚美辛组和大剂量广痛消泡沫气雾剂组PGE2浓度明显低于模型组(p=0.0023,p=0.0415),吲哚美辛组亦明显低于大剂量广痛消组(p=0.0410)。
(4)脊髓NR2B阳性神经元细胞数
小剂量广痛消组与模型组相比无显著差异(p=0.6563)；中剂量广痛消组、大剂量广痛消组、GTN组和吲哚美辛组阳性神经元细胞数明显少于模型组(p=0.0496,p=0.0125,p=0.0465,p=0.0242)；大剂量广痛消组阳性神经元细胞数明显少于吲哚美辛组(p=0.0128),中剂量广痛消组阳性神经元细胞数与吲哚美辛组无显著差异(p=0.0997),GTN组阳性神经元数目明显多于吲哚美辛组(p=0.0454)。
4结论
广痛消泡沫气雾剂和硝酸甘油软膏用于治疗慢性肛裂时都能显著缓解慢性肛裂患者的疼痛,降低肛管静息压,改善患者生活质量(躯体疼痛、生理职能和精力),两者治愈率无显著差异。但是广痛消泡沫气雾剂具有止痛速度更快和疗程更短的优势。此外广痛消泡沫气雾剂治疗过程中未见明显副作用。疗效与相关因素分析显示,广痛消对于病程较短者疗效较佳,治疗Ⅱ期肛裂疗效优于Ⅲ期肛裂。
广痛消泡沫气雾剂治疗肛裂的机制可能有：通过提高肛门内括约肌局部NO浓度缓解括约肌痉挛；通过抑制炎性因子PGE2生成和脊髓背角NR2B的表达抑制炎性痛痛觉敏化,而且上述作用有一定的量效关系,剂量越大,作用越明显。
1 Objectives
Studies of chronic anal fissure have made new progress in recent years. Firstly, the studies of the traditional drugs and classic operations have obtained more reliable datas, which will provide favorable evidence to support clinical decision-making; secondly, Some new drugs such as Gonyautoxin, phosphodiesterase inhibitor, L-arginine and muscarinic agonists and angiotensin-converting enzyme inhibitors are being researched; and the improvements to the traditional operations and bold innovations of the new operations are ongoing at the same time. Although the traditional medication treatments have lower cost, the cure rate of them are not high, meanwhile the side effects and long-term recurrence rate are high, so the compliance of patients to these treatments are not very good. Al though the cure rate of surgical therapies are relatively high, there are a certain risks of fecal incontinence, and the treatment cost is also higher.
Our previous studies have showed that the Guangtongxiao foam aerosol (GTX) has significant effects on pain relieving and spasmolysis in addition to certain effects of anti-inflammatory hemostatic and wound healing on a variety of anorectal diseases. The objectives of this subject are to observe the efficacy of GTX in the treatment of chronic anal fissure, and to study its mechanism of action from relieving the internal anal sphincter spasm and inhibition to the hyperalgesia of inflammatory pain.
2 Methods
This study consists of three parts. The first part is the literature research by reviewing the previous studies of GTX and the progress of treatment of chronic anal fissure and hyperalgesia research in molecular biology. We hope to find research targets in the study of mechanisms of GTX in the treatment of chronic anal fissure. The second part is the clinical efficacy research of GTX. We adopted randomized controlled approach to compare the efficacy of GTX and GTN from cure rate, pain relieving, reducing of anal resting pressure and improving to the quality of life, meanwhile we paid close attention to the side effects and and long-term recurrence rate of both drugs during the treatment and the follow-up. The third part is about the animal studies of GTX. We demonstrated the feasibility of the model of chronic anal fissure in rats by the observation of pain behaviors, pathology and bowel movement of the rats before and after the molding in experiment one; we compared the efficacy of various drugs in rats with chronic anal fissure from the perspective of pain behaviors in the second experiment; we adopted the nitrate reductase method to measure the concentration of NO in experiment three, to study the relation between GTX and the important neurotransmitter of internal anal sphincter; we adopted enzyme linked immunosorbent assay to measure concentration of PGE2 in serum in experiment four to study the relation between GTX and PGE2which is an important inflammatory factor; We adopted immunohistochemistry to detect NR2B expression in the spinal cord of rats to study the impact of GTX on the important receptor of hyperalgesia in experiment five.
3 Results
3.1 clinical research
(1)the cure rate:The cure rate of GTX was 56.25%, while the cure rate of glyceryl trinitrate ointment (GTN) was 51.61%, and there was no significant difference between them(p=0.5838);
(2)anal resting pressure:The anal resting pressures of both groups decreased significantly after the treatment (both p were less than 0.0001); and there was no significant difference between the two groups after the treatment (p=0.6843);
(3) pain scores:Pain of both groups alleviated significantly after the treatment(p=0.0011, p=0.0038), but there was no significant difference (p=0.5654) between the two groups after the treatment; pain of both groups alleviated significantly (p=0.0231, p=0.0386) at the 7th day of the treatment, and the treatment group alleviated more significantly than the control group (p=0.0176); pain of both groups alleviated significantly (p=0.0178, p=0.0255) at the 14th day than those of the 7th day, and the treatment group alleviated more significantly than the control group (p=0.0148); pain of both groups alleviated significantly (p=0.0258, p=0.0169) at the 21th day than those of the 14th day, and the treatment group alleviated more significantly than the control group (p=0.0315); pain scores of the treatment group did not decreased significantly ever since the 28th day of the treatment(p=0.3265, p=0.5284, p=0.5324), but the control group decreased all the time until the end of the treatment (p=0.0232, p=0.0154, p=0.0373); but the pain scores of the treatment group were still significantly lower than those of the control group (p=0.0139, p=0.0468), no significant difference existed between the two groups at the 42th day of the treatment (p=0.5654).
(4) quality of life:①bodily pain:both groups decreased significantly (p=0.0159, p=0.0278) after the treatment, but no significant difference(p=0.8621)existed between the two groups after the treatment;②role physical:both groups decreased significantly (p=0.0306, p=0.0351)after the treatment, but no significant difference (p=0.9781)existed between the two groups after the treatment;③vitality:both groups decreased significantly (p=0.0387, p=0.0405) after the treatment, but no significant difference (p=0.2572) existed between the two groups after the treatment; (4) there was no significant change about the physical functioning, general health, social functioning, role emotional and mental health (all p were greater than 0.05).
(5)Analysis to the relationship between efficacy of the treatment group and relevant factors:efficacy of the treatment group had relationship with duration of disease and anal fissure stage (p=0.0079, p=0.0168); no significant relationship was observed between efficacy and gender/age (p=0.9730, p=0.3295).
(6)side effects:seven patients in the control group (20%) had mild headache in the course of treatment, and three of them withdrew from the study because of headache-prone. There was no significant side effects in the treatment group in the course of treatment, significant difference existed between them(p=0.0112).
(7)relapse rate:the relapse rate of the control group (29.41%) was higher than that of the treatment group (11.11%)in the follow-up,but no statistical significance existed between them(p=0.2285).
3.2 zoopery research
(1)pain behavior tests
MWT:MWT of the low-dose group of GTX did not change significantly (p=0.4059) after the treatment; MWT of the middle-dose group of GTX, large-dose group of GTX, GTN group and the indomethacin group rised significantly (p=0.0346, 0.0105, p=0.0226, p=0.0188)at the end of the treatment; there was no significant difference among the middle-dose group of GTX, GTN group and the indomethacin group (all p were greater than 0.05); MWT of the large-dose group of GTX was significantly higher than that of the indomethacin group (p=0.0454).
TWL:TWL of the low-dose group of GTX didn't change significantly (p=0.1558) after the treatment; TWL of the middle-dose group of GTX, large-dose group of GTX, GTN group and the indomethacin group rised significantly (p=0.0231, p=0.0117, p=0.0265, p=0.0185) at the end of the treatment; there was no significant difference among the middle-dose group of GTX, GTN group and the indomethacin group (all p were greater than 0.05); TWL of the large-dose group of GTX was significantly higher than that of the indomethacin group (p=0.0433).
(2)concentration of NO in the local organization The concentration of NO of the low-dose group of GTX, middle-dose group of GTX and the indomethacin group were not significantly different with model group (p=0.3073, p=0.1734, p=0.3317); but that of GTN group was significantly higher than those of the model group (p=0.0121) and large-dose group of GTX (p=0.0108).
(3)serum concentration of PGE2 The serum concentration of PGE2 of the low-dose group of GTX, middle-dose group of GTX and the GTN group were not significantly different from model group (p=0.7760, p=0.0869, p=0.7053); but that of indomethacin group was significantly higher than those of the model group (p=0.0023) and large-dose group of GTX (p=0.0410).
(4)numbers of NR2B positive neurons in the spinal cord There was no significant difference between the low-dose group of GTX and the model group (p=0.6563); and the numbers of NR2B positive neurons of the middle-dose group of GTX, the large-dose group of GTX, the GTN group and the indomethacin group were all less than the model group remarkably (p=0.0496, p=0.0125, p=0.0465, p=0.0242); the number of NR2B positive neurons of the large-dose group of GTX was less than the indomethacin group remarkably(p=0.0128); there was no significant difference between the middle-dose group of GTX and the indomethacin group (p=0.0997); and the number of NR2B positive neurons of the GTN group was more than the indomethacin group (p=0.0454).
4 Conclusions
GTX and GTN could both relieve the pain of patients, reduce anal resting pressure, and improve patients'quality of life (bodily pain, role physical and vitality) significantly in treating patients with chronic anal fissure, no significant differences were observed in the cure rate. But GTX could relieve the pain more quickly and cured the chronic anal fissure in shorter course of treatment. Besides, no significant side effects were observed in the research. The analysis between efficacy and correlative factors showed that the shorter course of disease the better efficacy, and GTX was more effective in treating stageⅡanal fissure than stage III anal fissure.
The mechanism of GTX in treating chronic anal fissure were:to alleviate sphincter spasm by increasing the local NO concentration in the internal anal sphincter; to inhibit inflammatory hyperalgesia by inhibiting the expression of inflammatory factors--PGE2 in the serum and the expression of NR2B in the spinal cord dorsal horn, and the greater the dose, the more obvious efficacy.
引文
[1]W. Brian Perry, Sharon,et al.Practice Parameters for the Management of Anal Fissures (3rd Revision) [J] Dis Colon Rectum,2010,53:1110-1115
[2]J. N. Lund, P.0. Nystrom, G. Coremans. An evidence-based treatment algorithm for anal fissure [J].Tech Coloproctol,2006,10:177-180
[3]Arroyo A,Perez F,Serrano P et al Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure:long-term results of a prospective randomized clinical and manometric study[J]. Am J Surg,2005,189:429-434
[4]Lund JN.Nitric oxide deficiency in the internal anal sphincter of patients with chronic anal fissure [J]. Int J Colorectal Dis,2005
[5]Coll ins EE,Lund NJ.A review of chronic anal fissure management [J]. Tech Coloproctol,2007,11:209-223
[6]Nelson RL. Non surgical therapy for anal fissure. Cochrane Database [J] Syst Rev,2006,4
[7]Gagliardi G,Pascariello A, Altomare DF et al. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J].Tech Coloproctol,2010,14:241-248
[8]Ayantunde AA, Debrah SA. Current Concepts in Anal Fissures. World [J] Journal of Surgery,2006,30:2246-2260
[9]PARELLADA C. Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment wirh sphincterotomy in treatment of chronic anal fissure: a two-year follow-up[J]. Dis. Colon Rectum,2004,47:437-443
[10]Tankova L,Yoncheva K,Kovatchki D.Topical anal fissure treatment: placebo-controlled study of mononitrate and trinitrate therapies [J].Int J Colorectal Dis,2009,24:461-464
[11]Rob HP,Hilgers RHP, Webb RC.Molecular Aspects of Arterial Smooth Muscle Contraction:Focus on Rho[J].Exp Biol Med (Maywood),2005,230:829-835
[12]Bielecki K,Kolodziejczak M.A prospective randomized trial diltiazem and glyceryl trinitrate ointment in the treatment of chronic anal fissure[J]. Colorectal Dis,2003,5:256-257
[13]Jonas M, Neal KR, Abercrombie JF,et al.A randomized trial of oral vs topical diltiazem for chronic anal fissures [J].Dis Colon Rectum,2001,44:1074-1078
[14]Nash GF, Kapoor K, Saeb-Parsy K, et al.The long-term results of diltiazem treatment for anal fissure[J]. Int J Clin Pract,2006,60:1411-1413
[15]Ezri T,Susmalliam S.Topical nifedipine vs. topical glyceryl trinitrate of chronic anal fissure[J]. Dis Colon Rectum,2003,46:805-808
[16]Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins:a review,part 1[J].Am J Health Syst Pharm,2006,63 (2):145-152
[17]Jones OM, Ramalingam T,Merrie A, et al. Randomized clinical trial of botulinum toxin plus glyceryl trinitrate vs. botulinum toxin alone for medically resistant chronic anal fissure:overall poor healing rates [J]. Dis Colon Rectum,2006,49:1574-1580
[18]Arroyo A,Perez F, Serrano P,et al. Long-term results of botulinum toxin for the treatment of chronic anal fissure:prospective clinical and manometric study[J]. Int J Colorectal Dis,2005,20:267-271
[19]Fruehauf H, Fried M, Wegmuel ler B, et al. Efficacy and safety of botul inum toxin compared with topical nytroglycerin oinment for the treatment of chronic anal fissure:a prospective randomized study[J]. Am J Gastroenterol,2006, 101:2107-2112
[20]Bhardwaj R, Drye E, Vaizey C. Novel delivery of botulinum toxin for the treatment of anal fissures[J]. Colorectal disease,2006,8 (4):360-364
[21]Lysy J, Israelit-Yatzkan Y,Sestiery-Ittah M, et al.Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure [J]. Gut,2001,48:221-224
[22]Essani R,Sarkisyan G, Beart RW, et al. Cost-saving effect of treatment algorithm for chronic anal fissure:a prospective analysis. [J] Gastrointest Surg,2005,9:1237-1244
[23]Wan-Jin Shao, Guo-Chun Li, Zhi-Kun Zhang. Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure [J]. Int J Colorectal Dis,2009,24:995-1000
[24]Lysy J,Israeli E,Levy S,et al. Long-term results of "chemical sphincterotomy" for chronic anal fissure:a prospective study [J].Dis Colon Rectum,2006,49 (6):858-864
[25]Garrido R, Lagos N,Lattes K. Gonyautoxin:New Treatment for Heal ing Acute and Chronic Anal Fissures [J]. Dis Colon Rectum,2005,48:335-343
[26]D. F. Altomare, G. A. Binda,S. Canuti. The management of patients with primary chronic anal fissure:a position paper[J]. Tech Coloproctol,2011,15:135-141
[27]Garry A,Fromy B, Blondeau N,et al. Altered acetylcholine, bradykinin and cutaneous pressure-induced vasodilation in mice lacking the TREK1 potassium channel:the endothelial link[J].EMBO Rep,2007,8:354-359
[28]Muthukumarassamy R, Robinson SS, Sarath SC,et al. Treatment of anal fissures using a combination of minoxidil and lignocaine:a randomized, double-blind trial [J]. Indian J Gastroenterol,2005,24:158-160
[29]Al-Hilli Z, Pritchard R, Roche-Nagle G, et al. Nicorandil related anal ulcer [J]. Ir J Med Sci,2006,175:62-63
[30]Takimoto E,Belardi D,Tocchetti CG,et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5[J]. Circulation,2007,115:2159-2167
[31]Ballester C,Sarria B,Garcia-Granero E, et al. Relaxation of the isolated human internal anal sphincter by sildenafil[J].Br J Surg,2007,94:894-902
[32]Gosselink MP, Darby M, Zimmerman DD, et al. Treatment of chronic anal fissure by application of L-arginine gel:a phase Ⅱ study in 15 patients [J]. Dis Colon Rectum,2005,48:832-837
[33]Prins HA, Gosselink MP,Mitales LE et al.The effect of oral administration of L-arginine on anal resting pressure and anodermal blood flow in healthy volunteers [J]. Tech Coloproctol,2005,9:229-232
[34]Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects [J]. Dis Colon Rectum,2000,43:1359-1362
[35]Khaikin M,Yebara S,Bashankaev B, et al.Topical Captopril Cream:A New Treatment for Anal Fissure?The First Human Study [J]. Dis Colon Rectum, 2007,50:747
[36]张金良.肛裂治验一得[J].中国民族民间医药,2008,1：54
[37]陈红风.中医外科学[M].北京：中国中医药出版社,2005。479
[38]张书信.活血柔肝法对肛门内括约肌影响及对肛裂治疗作用的研究[D].北京.北京中医药大学,2004
[39]王浩,曹文广.中西医结合治疗慢性肛裂80例[J].内蒙古中医药,2008,3：37
[40]李海光,仲怀中.金黄散调膏治疗慢性肛裂[J].中国民族民间医药,2010,18：70
[41]朱汉章.针刀医学体系概论[J].中国工程科学,2006,8(7)：1-15
[42]杨苏琴,万顺兰,晁希平.微创小针刀治疗肛裂47例[J].内蒙古医学杂志,2011,42(2)：32-33
[43]王久刚,李东冰,苗春红.小针刀内括约肌切断术治疗慢性肛裂的临床评价[J].内蒙古医学杂志,2011,43(2)：152-154
[44]安少雄,黄斌.小针刀治疗肛裂的临床研究[J].北京医学,2011,33(4)：303-305
[45]李兆俊,岳美荣.小针刀松解加综合疗法治疗陈旧性肛裂265例临床观察[J].中国民康医学,2008,20(2)：98
[46]应光耀,张志君,沙喜.特型小针刀对侧切术治疗慢性肛裂50例临床观察[J].河北中医,2011,33(4)：522-523
[47]王蓉荻,王竞,詹娇阳,等.搔刮加小针刀内括约肌切断术治疗肛裂的临床效果观察[J].安徽医药,2011,15(3)：324-326
[48]郝秀艳,文丽娟,谢祥锟.肛漏古籍挂线疗法探析[J].山东中医药大学学报,2011,35(1)：56-57
[49]唐培龙.肛裂患者挂线术的治疗体会[J].中国医药导报,2008,5(36)：49-50
[50]刘仍海,张燕生,张书信,等.中医挂线疗法治疗肛裂120例临床观察[J].中医杂志,2010,51(5)：416-418
[51]梁戎.侧方内括约肌挂线术与切断术治疗肛裂疗效比较[J].中外医疗,2011,3：89
[52]Rosa G, Lolli P,Piccinelli D,et al. Calibrated lateral internal sphincterotomy for chronic anal fissure [J]. Tech Coloproctol,2005,9:127-132
[53]Nelson RL, Chattopadhyay A, Brooks W. Operative procedures for fissure in ano [J].Cochrane Database of Systematic Reviews,2011
[54]Mentes BB, Tezcaner T,Yilraaz U, et al. Results of lateral internal sphincterotomy for chronic anal fissure with particular reference to quality of life[J]. Dis Colon Rectum,2006,49:1045-1051
[55]Renzi A, Izzo D, Di Sarno G, et al. Clinical, manometric,and ultrasonographic results of pneumatic balloon dilatation vs. lateral internal sphincterotomy for chronic anal fissure:a prospective, randomized, controlled trial [J].Dis Colon Rectum,2008,51:121-127
[56]Baraza W, Boereboom C, Shorthouse A, et al.The long-term efficacy of fissurectomy and botulinum toxin injection for chronic anal fissure in females [J]. Dis Colon Rectum,2008,51:236-243
[57]Mentes BB,Ege B, Leventoglu S,et al.Extent of lateral internal sphincterotomy:up to the dentate line or up to the fissure apex? [J]. Dis Colon Rectum,2005,48:365-370
[58]Elsebae MM. A study of fecal incontinence in patients with chronic anal fissure:prospective, randomized, controlled trial of the extent of internal anal sphincter division during lateral sphincterotomy [J]. World J Surg, 2007,31:2052-2057
[59]Ho, KS, Ho KY. Randomized clinical trial comparing oral nifedipine with lateral anal sphincterotomy and tailored sphincterotomy in the treatment of chronic anal fissure [J]. Br J Surg,2005,92:403-408
[60]Cho DY. Controlled lateral sphincterotomy for chronic anal fissure[J]. Dis Colon Rectum,2005,48:1037-1041
[61]Rotholtz NA, Bun M, Mauri MV, et al. Long-term assessment of fecal incontinence after lateral internal sphincterotomy[J]. Tech Coloproctol 2005,9:115-118
[62]Madoff RD, Steele SR Anorectal manometry and anal fissure treatment:authors' reply[J]. Aliment Pharmacol Ther,2006,24:1652
[63]S. R. Mousavi,M. Sharifi, Zohreh Mehdikhah. A Comparison Between the Results of Fissurectomy and Lateral Internal Sphincterotomy in the Surgical Management of Chronic Anal Fissure[J].J Gastrointest Surg,2009,13:1279-1282
[64]Engel AF,Eijsbouts QA, Balk AG Fissurectomy and isosorbide dinitrate for chronic fissure in ano not responding to conservative treatment[J]. Br J Surg,2002,89:79-83
[65]Lindsey I, Cunningham C, Jones OM, et al. Fissurectomy-botul inum toxin:a novel sphinctersparing procedure for medically resistant chronic anal fissure [J]. Dis Colon Rectum,2004,47:1947-1952
[66]Renzi A, Izzo D, Di Sarno G. Clinical,Manometric,and Ultrasonographic Results of Pneumatic Balloon Dilatation vs Lateral Internal Sphincterotomy for Chronic Anal Fissure:A Prospective, Randomized, Controlled Trial[J]. Diseases of the Colon and Rectum.2008,51(1):121-127
[67]Boschetto S, Giovannone M, Tosnoni M, et al. Hydropneumatic anal dilatation in conservative treatment of chronic anal fissure:clinical outcomes and randomized comparison with topical nitroglycerin[J] Tech Coloproctol 2004; 8:89-93
[68]Tayfun Yucel,Dogan Gonullu,Mahmut Oncu. Comparison of controlled-intermittent anal dilatation and lateral internal sphincterotomy in the treatment of chronic anal fissures:A prospective, randomized study [J]. International Journal of Surgery,2009,7:228-231
[69]Giordano P,Gravante G,Grondona P, et al. Simple cutaneous advancement flap anoplasty for resistant chronic anal fissure:a prospective study[J]. World J Surg,2009,33(5):1058-1063
[70]Nyam DCNK, Wilson RG,Stewart KJ,et al. Island advancement flaps in the management of anal fissures[J].Br J Surg,2005,82 (3):326-328
[71]Kenefick NJ,Gee AS,Durdey P.Treatment of resistant anal fissure with advancement noplasty [J].Colorectal Dis,2002,4 (6):463-466
[72]Cross KL, Massey EJ, Fowler AL,et al. ACPGBI. The management of anal fissure: ACPGBI position statement[J]. Colorectal Dis,2008,10 (3):1-7
[73]Rigotti G,Marchi A,Galie M,et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant:a healing process mediated by adipose-derived adult stem cells [J]. Plast Reconstr Surg.2007; 119:1409-1422
[74]Lolli P, Malleo G, Rigotti G. Treatment of chronic anal fissures and associated stenosis by autologous adipose tissue transplant:a pilot study [J]. Dis Colon Rectum,2010,53:460-466
[1]Sandkuhler, Jurgen. Models and Mechanisms of Hyperalgesia and Allodynia [J]. Physiological Reviews.2009,89 (2):707-758
[2]Nakagawa T,Wakamatsu K,Zhang N,et al. Intrathecal administration of ATP produces long-lasting allodynia in rats:differential mechanisms in the phase of the induction and maintenance[J]. Neuroscience,2007,147:445-455
[3]张恒.SP与脊髓星形胶质细胞活化的关系及在大鼠慢性前列腺炎疼痛中的作用探讨[D].重庆.第三军医大学,2007
[4]Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? [J].Acta Physiol(Oxf),2006,187(12):321-327
[5]Hatashita S, Sekiguchi M, Kobayashi H, et al. Contra lateral neuropathic pain and neuropathology in dorsal root ganglion and spinal cord following hemilateral nerve injury in rats [J].Spine,2008,33 (12):1344-1351
[6]Fu D,Guo QL,YH Ai,et al.Glial Activation and segmental upregulation of inter leukin-1 β after surgical incision [J]. Neurochem Res,2006,31:333-340
[7]张文华,江剑平.白介素-1β在炎性痛中的作用及其机制[J].生命科学,2010,22(3)：291-295
[8]Scott DL,Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis[J].N Eng J Med 2006,355:704-712
[9]Zeilhofer HU.Prostanoids in nociception and pain [J]. Biochem Pharmacol, 2007,73:165-174
[10]韩彬彬,冯艺.环氧化酶-1在坐骨神经冷冻致神经病理性疼痛模型大鼠脊髓的表达.[J].中国康复理论与实践,2010,16(6)：528-531
[11]梁纯波,傅迪,郭曲练,等.脊髓肿瘤坏死因子-alpha(TNF-α)促进切割损伤导致的痛觉过敏[J].现代生物医学进展,2009,9(9)：1635-1637
[12]Taylor PC, Feldmann M. Anti-TNF biologic agents:still the therapy of choice for rheumatoid arthritis[J]. Nat Rev Rheumatol 2009; 5:578-582
[13]Cohen SP, Bogduk N,Dragovich A, et al. Randomized, double-blind, placebocontrolled,dose-response,and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica [J].Anesthesiology 2009,110:1116-1126
[14]Alvira CM,Abate A,Yang G, et al. Nuclear Factor-kB Activation in Neonatal Mouse Lung Protects against Lipopolysaccharideinduced Inflammation Am J Respir Crit Care Med.2007; 175:805-815
[15]Ndengele MM, Cuzzocrea S,Esposito E, et al. Cyclooxygenases land 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity[J]. FASEB J.2008; 22:3154-3164
[16]Sophie Pezet, Stephen, B. McMahon. Neurotrophins:Mediators and Modulators of Pain[J]. Annual Review of Neuroscience.2006,29:507-538
[17]McMahon SB,Bennett DL,Bevan S. Inflammatory mediators and modulators [J]. Textbook of Pain,2006,1,49-72
[18]聂发传,王金保,苏东等.补体抑制剂对大鼠神经病理性疼痛模型的作用研究[J].中国疼痛医学杂志,2009,15(4)：240-242
[19]Sasaki A,Mabuchi T, Serizawa K, et al.Different roles of nitric oxide synthase-1 and-2 between herpetic and postherpetic allodynia in mice. Neuroscience,2007,150:459-466
[20]刘艳阳,胡兴国,曾因明.鞘内注射硫酸镁或/和吗啡对大鼠切口疼痛的影响[J].国际麻醉学与复苏杂志,2007,28(6)：497-501
[21]闫俊强,杨金升.N-甲基-D-天冬氨酸受体2B亚基与疼痛[J].医学综述,2008,14(8)：1153-1155
[22]林春,林国威,郑伟等.NMDA受体NR2B亚单位在慢性内脏痛觉敏化中的作用[J].中国药理学通报,2008,24(8)：1015-1018
[23]张晓琴,彭章龙,于布为.Non-NMDA受体在术后痛觉过敏中作用的研究进展[C]//方慧.2008年第七次华东六省一市麻醉学学术会议暨浙江省麻醉学术年会论文汇编(上册).杭州：杭州出版社,2008
[24]Lee SE, Kim JH. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat[J].Neurosci Res,2007,58:245-249
[25]Li D, Ren Y, Xu X, et al. Sensi tization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related peptide driven by dorsal root [J]. Pain,2008,9(12):1155-1168
[26]Greco R,Tassorelli C,Sandrini G,et al.Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia,2008,28 (2):114-126
[27]王英,鄢建勤.P2X3受体在疼痛机制中的作用[J].中国疼痛医学杂志,2009,15(3)：177-179
[28]Inoue K.Purinergic systems in microglia[J]. Cell Mol Life Sci,2008,65: 3074-3080
[29]李娜,崔可密,李为民.Y-氨基丁酸递质及其受体系统在痛觉中的作用[J].国际麻醉学与复苏杂志,2007,28(4)：342-245
[30]Graham ES,Ashton JC, GlassM. Cannabinoid Receptors:A briefhistory and "what's hot" [J].Front Biosci,2009,1:944-957
[31]Tohno M, Shimazu T, Aso H, et al. Molecular cloning and functional characterization of porcine MyD88 essential for TLR signaling [J].Cell Mol Immunol,2007,4:369-376
[32]Dib-Hajj SD,Cummins TR,Black JA,et al. Sodium channels in normal and pathological pain[J]. Annu Rev Neurosci,2010,33:325-347
[33]Cox JJ, Sheynin J,Shorer Z, et al. An SCN9A channelopathy causes congenital inability to experience pain[J]. Nature,2006,444:894-898
[34]张瑞,王清秀,郭慧琴.大鼠坐骨神经损伤性疼痛的行为观察和背根神经节中KvlmRNA的表达[J].现代医药卫生,2009,25(2)：165-166
[35]蒋兴凯,陈蕾,马冲.N-型钙通道及其阻断剂研究进展[J].国外医学药学分册报,2007,34(2)：93-98
[36]吴飞翔,俞卫锋.T型钙通道与疼痛[J].国际麻醉学与复苏杂志,2007,28(6)：565-567
[37]Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management[J]. Neurotherapeutics,2009,6:679-692
[38]Ikeuchi M,Kolker SJ,Burnes LA,et al.Role of ASIC3 in the primary and secondary hyperalgesia produced by joint inflammation in mice[J]. Pain, 2008,137 (3):662-669
[39]JiRR, GereauRW, MalcangioM, et al. MAP kinase and pain.Brain Res Rev,2009,60: 135-148
[40]Roberts LA, Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia; recent patents on CNS[J].Drug Dis,2006,1:65-76
[41]雷洪伊.脊髓ERK活化在瑞芬太尼引起术后痛觉过敏中的作用[D].广州.南方医科大学,2010
[42]卢国林.氟比洛芬醋预处理对急性疼痛大鼠抗伤害效应[D].福州,福建医科大学,2008
[43]龚琴,胡兴国,刘艳阳等.脊髓背角p38 MAPK活化在大鼠切口痛形成中的作用[J].中国疼痛医学杂志,2009,15(4)：226
[44]陈百红,陈雄刚,林财珠.氟比洛芬酯对手术致痛大鼠脊髓Fos蛋白表达的影响[J].现代生物医学进展,2009,9(15)：2824-2826
[1]彭俊付,刘勇,刘永刚.正交试验法优选广痛消中芍药苷的提取工艺[J].北京中医药大学学报,2011,34(4)：271-275
[2]彭俊付.广痛消泡沫气雾剂经直肠粘膜渗透率试验研究及其止痛与安全性临床观察[D].北京.北京中医药大学,2011
[3]彭俊付,赵宝明,张书信.RP-HPLC测定广痛消中芍药苷含量的方法[J].中国中药杂志,2011,36(23)：3268-3269
[4]吴振宇,吴广均,赵宝明.广痛消泡沫气雾剂的止痛解痉作用[J].中国中药杂志,2001,26(8)：559-561
[5]Cull-Candy S,Brickley S,FarrantM. NMDA receptor subunits:diversity, development and disease[J]. Curr Op Neurobiol,2001,11 (3):327
[6]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35
[7]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[8]王晓光,傅江南.常用中药药理研究与临床运用[M].北京：人民军医出版社,2006：220
[9]王红,田明,王淼,等.延胡索现代药理及临床研究进展[J].中医药学报,2010,38(6)：110
[10]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[11]酒淑玲.广痛消泡沫气雾剂促进混合痔术后创面愈合的临床研究[D].北京.北京中医药大学,2011
[12]陈美婉,陈听,潘昕,等.药用泡沫气雾剂的研究和应用概况[J].药学进展,2009,33(12)：549-551
[13]胡博.广痛消泡沫气雾剂剂型优势性研究[D].北京.北京中医药大学,2011
[1]Perry WB, Dykes SL, Buie WD. Practice Parameters for the Management of Anal Fissures (3rd Revision) [J].Dis Colon Rectum,2010,53:1110-1115
[2]G. Gagliardi,A. Pascariello, D. F. Altomare et al. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J]. Tech Coloproctol,2010,14:241-248
[3]Lysy J, Israeli E, Levy S, et al. Long-term results of "chemical sphincterotomy" for chronic anal fissure:a prospective study[J]. Dis Colon Rectum,2006,49: 858-864
[4]Nelson RL. Non surgical therapy for anal fissure. Cochrane Database [J] Syst Rev, 2006,4
[5]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35
[6]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[7]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[8]E. E. Collins,J. N. Lund. A review of chronic anal fissure management[J]. Tech Coloproctol,2007,11:209-223
[9]梅全喜.现代中药药理与临床应用手册[M].北京：中国中医药出版社,2008：790
[10]王晓光,傅江南.常用中药药理研究与临床运用[M].北京：人民军医出版社,2006：409
[11]Brodie BC. Lectures on diseases of the rectum, lecture Ⅲ:preternatureal contraction of the sphincter ani[J].Lond Med Gaz,1835,16:26-31
[12]Lin JK. Anal manometric studies in hemorrhoids and anal fissures [J]. Dis Colon Rectum,1989,32:839-842
[13]Khaikin M, Yebara S, Bashankaev B, et al. Topical Captopril Cream:A New Treatment for Anal Fissure?The First Human Study[J]. Dis Colon Rectum, 2007,50:747
[14]Gr iff in N,Acheson AG, Tung P, et al. Quality of life in patients with chronic anal fissure[J]. Colorectal Dis,2004,6:39-44
[15]Lund JN, Parson SL, Scholefield JH. Spasm of internal anal sphincter in anal fissure-cause or effect?[J]. Gastroenterology,1996,110:711
[16]Bailey HR,Beck DE, Billingham RP,et al.Fissure Study Group. A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures[J]. Dis Colon Rectum,2002,45: 1192-1199
[17]Graziano A,Svidler Lopez L,Lencinas S, et al. Long-term results of topical nitroglycerin in the treatment of chronic anal fissures are disappointing [Jl.Tech Coloproctol,2001,5:143-147
[18]Jensen SL.Maintenance therapy with unprocessed bran in the prevention of acute anal fissure recurrence [J]. J R Soc Med,1987,80:296-298
[19]胡博.广痛消泡沫气雾剂剂型优势性研究[D].北京.北京中医药大学,2011
[1]E.E. Collins, J. N. Lund. A review of chronic anal fissure management [J]. Tech Coloproctol,2007,11:209-223
[2]陈奇.中药药理研究方法学[M].第一版.北京：人民卫生出版社,1993.1103
[3]G.Gagliardi,A.Pascariello, D. F. Altomare. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J].Tech Coloproctol,2010,14:241-248
[4]赵雨千,陈绍宗,李强等.对Beitz大鼠后肢穿刺伤疼痛模型进行改良的实验研究[J].中国疼痛医学杂志,2010,10(21)：4022-4024
[5]Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity[J]. Nature,1983,306:686-88
[6]Stebbing JF. Nitric oxide synthase neurones and neuromuscular behaviour of the anorectum[J]. Ann R Coll Surg Engl,1998,80:137-145
[7]Lund JN.Nitric oxide deficiency in the internal anal sphincter of patients with chronic anal fissure [J].Int J Colorectal Dis,2005
[8]L'Hopital F,Michelland 0, Lunaud B,et al. Constipation et hypertonie du sphincter interne de lanus:response sphincterienne a ladministration sub-linguale de 0.40 mg de Natispray [J]. Gastroenterol Clin Biol,1990,14:268
[9]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[10]雒建瑞,王长淼,傅雷,等.芍药甙对家兔离体oddi括约肌肌环收缩活动的影响[J].大连医科大学学报,2009,31(6)：668-671
[11]Kassuya, C. A, J. Ferreira, R. F. Claudino, et al. Intraplantar PGE2 causes nociceptive behavior and mechanical allodynia:the role of prostanoid E receptors and protein kinases [J]. Br J Pharmacol,2007,150(6):727-737
[12]Turnbach, M. E, DS. Spraggins, and A.Randich. Spinal administration of prostaglan E (2) or prostaglandin F(2alpha) primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons [J]. Pain,2002,97(1-2):33-45
[13]Julius D, Basbaum Al.Molecular mechanisms of nociception [J].Nature,2001, 413:203-210
[14]Dolan S, Kelly JG,Huan M,et al.Transient up-regulation of spinal cyclooxygenase-2 and neuronal nitric oxide synthase following surgical inflammation[J]. Anesthesiology,2003,98:170-180
[15]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[16]C. Beinat, S. Banister,I. Moussa, et al.Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists[J]. Current Medicinal Chemistry,2010,17 (34):4166-4190
[17]林春,林国威,郑伟等.NMDA受体NR2B亚单位在慢性内脏痛觉敏化中的作用[J].中国药理学通报,2008,24(8)：1015-1018
[18]Blaise ML, Sowdhamini R, Rao MR, et al. Evolutionary trace analysis of ionotropic glutamate receptor sequences and modeling the interactions of agonists with different NMDA receptor subunits [J]. Mol Model,2004,10 (5-6): 305-316
[19]Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunison Primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats [J]. Neuroscience,2000,101(3):699-707
[20]Nagy GG, Watanabe M, Fukaya M, et al. Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique[J]. Eur JNeurosci, 2004,20(12):3301-3312
[21]马江红.NR2B在糖尿病神经痛大鼠脊髓背角表达的变化[D].石家庄.北河北医科大学,2011
[22]Luque JM,Bleuel Z,Malherbe P, et al. Alternatively spliced isoforms of the N-methyl-D-aspartate receptor subunitl are differentially distributed within the rat spinal cord[J]. Neuroscience,1994,63 (90):629-635
[23]Lo Grasso P,Mckelvy J.Advances in Pain therapeutics[J]. Currop in Chem Biol,2003,7(4)452-456
[24]Tan PH, Yang LC, Shin HC, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat [J].GeneTherapy,2005,12(1):59-66
[25]陈建平,田玉科,杨少兵.腹腔注射NR2B抗体对大鼠慢性神经病理性痛的镇痛效应[J].山西医科大学学报,2008,7：559-561
[26]Wang GM,Tian XB, Chen JP,et al. Prevention of neuropathic pain in an animal model of spare nerve injury following oral immunization with recombinant adenovirus serotype 5-mediated NR2B gene transfer [J]. GeneTher,2007, 14(24):1681-1687
[27]CaisO, Sed lacek M,Horak M, et al. Temperature dependence of NR1-NR2B NMDA receptor channels [J].Neuroscience,2008,151 (2):428-438
[28]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35
[2]J. N. Lund, P.0. Nystrom, G. Coremans. An evidence-based treatment algorithm for anal fissure [J].Tech Coloproctol,2006,10:177-180
[3]Arroyo A,Perez F,Serrano P et al Surgical versus chemical (botulinum toxin) sphincterotomy for chronic anal fissure:long-term results of a prospective randomized clinical and manometric study[J]. Am J Surg,2005,189:429-434
[4]Lund JN.Nitric oxide deficiency in the internal anal sphincter of patients with chronic anal fissure [J]. Int J Colorectal Dis,2005
[5]Coll ins EE,Lund NJ.A review of chronic anal fissure management [J]. Tech Coloproctol,2007,11:209-223
[6]Nelson RL. Non surgical therapy for anal fissure. Cochrane Database [J] Syst Rev,2006,4
[7]Gagliardi G,Pascariello A, Altomare DF et al. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J].Tech Coloproctol,2010,14:241-248
[8]Ayantunde AA, Debrah SA. Current Concepts in Anal Fissures. World [J] Journal of Surgery,2006,30:2246-2260
[9]PARELLADA C. Randomized, prospective trial comparing 0.2 percent isosorbide dinitrate ointment wirh sphincterotomy in treatment of chronic anal fissure: a two-year follow-up[J]. Dis. Colon Rectum,2004,47:437-443
[10]Tankova L,Yoncheva K,Kovatchki D.Topical anal fissure treatment: placebo-controlled study of mononitrate and trinitrate therapies [J].Int J Colorectal Dis,2009,24:461-464
[11]Rob HP,Hilgers RHP, Webb RC.Molecular Aspects of Arterial Smooth Muscle Contraction:Focus on Rho[J].Exp Biol Med (Maywood),2005,230:829-835
[12]Bielecki K,Kolodziejczak M.A prospective randomized trial diltiazem and glyceryl trinitrate ointment in the treatment of chronic anal fissure[J]. Colorectal Dis,2003,5:256-257
[13]Jonas M, Neal KR, Abercrombie JF,et al.A randomized trial of oral vs topical diltiazem for chronic anal fissures [J].Dis Colon Rectum,2001,44:1074-1078
[14]Nash GF, Kapoor K, Saeb-Parsy K, et al.The long-term results of diltiazem treatment for anal fissure[J]. Int J Clin Pract,2006,60:1411-1413
[15]Ezri T,Susmalliam S.Topical nifedipine vs. topical glyceryl trinitrate of chronic anal fissure[J]. Dis Colon Rectum,2003,46:805-808
[16]Cheng CM, Chen JS, Patel RP. Unlabeled uses of botulinum toxins:a review,part 1[J].Am J Health Syst Pharm,2006,63 (2):145-152
[17]Jones OM, Ramalingam T,Merrie A, et al. Randomized clinical trial of botulinum toxin plus glyceryl trinitrate vs. botulinum toxin alone for medically resistant chronic anal fissure:overall poor healing rates [J]. Dis Colon Rectum,2006,49:1574-1580
[18]Arroyo A,Perez F, Serrano P,et al. Long-term results of botulinum toxin for the treatment of chronic anal fissure:prospective clinical and manometric study[J]. Int J Colorectal Dis,2005,20:267-271
[19]Fruehauf H, Fried M, Wegmuel ler B, et al. Efficacy and safety of botul inum toxin compared with topical nytroglycerin oinment for the treatment of chronic anal fissure:a prospective randomized study[J]. Am J Gastroenterol,2006, 101:2107-2112
[20]Bhardwaj R, Drye E, Vaizey C. Novel delivery of botulinum toxin for the treatment of anal fissures[J]. Colorectal disease,2006,8 (4):360-364
[21]Lysy J, Israelit-Yatzkan Y,Sestiery-Ittah M, et al.Topical nitrates potentiate the effect of botulinum toxin in the treatment of patients with refractory anal fissure [J]. Gut,2001,48:221-224
[22]Essani R,Sarkisyan G, Beart RW, et al. Cost-saving effect of treatment algorithm for chronic anal fissure:a prospective analysis. [J] Gastrointest Surg,2005,9:1237-1244
[23]Wan-Jin Shao, Guo-Chun Li, Zhi-Kun Zhang. Systematic review and meta-analysis of randomized controlled trials comparing botulinum toxin injection with lateral internal sphincterotomy for chronic anal fissure [J]. Int J Colorectal Dis,2009,24:995-1000
[24]Lysy J,Israeli E,Levy S,et al. Long-term results of "chemical sphincterotomy" for chronic anal fissure:a prospective study [J].Dis Colon Rectum,2006,49 (6):858-864
[25]Garrido R, Lagos N,Lattes K. Gonyautoxin:New Treatment for Heal ing Acute and Chronic Anal Fissures [J]. Dis Colon Rectum,2005,48:335-343
[26]D. F. Altomare, G. A. Binda,S. Canuti. The management of patients with primary chronic anal fissure:a position paper[J]. Tech Coloproctol,2011,15:135-141
[27]Garry A,Fromy B, Blondeau N,et al. Altered acetylcholine, bradykinin and cutaneous pressure-induced vasodilation in mice lacking the TREK1 potassium channel:the endothelial link[J].EMBO Rep,2007,8:354-359
[28]Muthukumarassamy R, Robinson SS, Sarath SC,et al. Treatment of anal fissures using a combination of minoxidil and lignocaine:a randomized, double-blind trial [J]. Indian J Gastroenterol,2005,24:158-160
[29]Al-Hilli Z, Pritchard R, Roche-Nagle G, et al. Nicorandil related anal ulcer [J]. Ir J Med Sci,2006,175:62-63
[30]Takimoto E,Belardi D,Tocchetti CG,et al. Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5[J]. Circulation,2007,115:2159-2167
[31]Ballester C,Sarria B,Garcia-Granero E, et al. Relaxation of the isolated human internal anal sphincter by sildenafil[J].Br J Surg,2007,94:894-902
[32]Gosselink MP, Darby M, Zimmerman DD, et al. Treatment of chronic anal fissure by application of L-arginine gel:a phase Ⅱ study in 15 patients [J]. Dis Colon Rectum,2005,48:832-837
[33]Prins HA, Gosselink MP,Mitales LE et al.The effect of oral administration of L-arginine on anal resting pressure and anodermal blood flow in healthy volunteers [J]. Tech Coloproctol,2005,9:229-232
[34]Carapeti EA, Kamm MA, Phillips RK. Topical diltiazem and bethanechol decrease anal sphincter pressure and heal anal fissures without side effects [J]. Dis Colon Rectum,2000,43:1359-1362
[35]Khaikin M,Yebara S,Bashankaev B, et al.Topical Captopril Cream:A New Treatment for Anal Fissure?The First Human Study [J]. Dis Colon Rectum, 2007,50:747
[36]张金良.肛裂治验一得[J].中国民族民间医药,2008,1：54
[37]陈红风.中医外科学[M].北京：中国中医药出版社,2005。479
[38]张书信.活血柔肝法对肛门内括约肌影响及对肛裂治疗作用的研究[D].北京.北京中医药大学,2004
[39]王浩,曹文广.中西医结合治疗慢性肛裂80例[J].内蒙古中医药,2008,3：37
[40]李海光,仲怀中.金黄散调膏治疗慢性肛裂[J].中国民族民间医药,2010,18：70
[41]朱汉章.针刀医学体系概论[J].中国工程科学,2006,8(7)：1-15
[42]杨苏琴,万顺兰,晁希平.微创小针刀治疗肛裂47例[J].内蒙古医学杂志,2011,42(2)：32-33
[43]王久刚,李东冰,苗春红.小针刀内括约肌切断术治疗慢性肛裂的临床评价[J].内蒙古医学杂志,2011,43(2)：152-154
[44]安少雄,黄斌.小针刀治疗肛裂的临床研究[J].北京医学,2011,33(4)：303-305
[45]李兆俊,岳美荣.小针刀松解加综合疗法治疗陈旧性肛裂265例临床观察[J].中国民康医学,2008,20(2)：98
[46]应光耀,张志君,沙喜.特型小针刀对侧切术治疗慢性肛裂50例临床观察[J].河北中医,2011,33(4)：522-523
[47]王蓉荻,王竞,詹娇阳,等.搔刮加小针刀内括约肌切断术治疗肛裂的临床效果观察[J].安徽医药,2011,15(3)：324-326
[48]郝秀艳,文丽娟,谢祥锟.肛漏古籍挂线疗法探析[J].山东中医药大学学报,2011,35(1)：56-57
[49]唐培龙.肛裂患者挂线术的治疗体会[J].中国医药导报,2008,5(36)：49-50
[50]刘仍海,张燕生,张书信,等.中医挂线疗法治疗肛裂120例临床观察[J].中医杂志,2010,51(5)：416-418
[51]梁戎.侧方内括约肌挂线术与切断术治疗肛裂疗效比较[J].中外医疗,2011,3：89
[52]Rosa G, Lolli P,Piccinelli D,et al. Calibrated lateral internal sphincterotomy for chronic anal fissure [J]. Tech Coloproctol,2005,9:127-132
[53]Nelson RL, Chattopadhyay A, Brooks W. Operative procedures for fissure in ano [J].Cochrane Database of Systematic Reviews,2011
[54]Mentes BB, Tezcaner T,Yilraaz U, et al. Results of lateral internal sphincterotomy for chronic anal fissure with particular reference to quality of life[J]. Dis Colon Rectum,2006,49:1045-1051
[55]Renzi A, Izzo D, Di Sarno G, et al. Clinical, manometric,and ultrasonographic results of pneumatic balloon dilatation vs. lateral internal sphincterotomy for chronic anal fissure:a prospective, randomized, controlled trial [J].Dis Colon Rectum,2008,51:121-127
[56]Baraza W, Boereboom C, Shorthouse A, et al.The long-term efficacy of fissurectomy and botulinum toxin injection for chronic anal fissure in females [J]. Dis Colon Rectum,2008,51:236-243
[57]Mentes BB,Ege B, Leventoglu S,et al.Extent of lateral internal sphincterotomy:up to the dentate line or up to the fissure apex? [J]. Dis Colon Rectum,2005,48:365-370
[58]Elsebae MM. A study of fecal incontinence in patients with chronic anal fissure:prospective, randomized, controlled trial of the extent of internal anal sphincter division during lateral sphincterotomy [J]. World J Surg, 2007,31:2052-2057
[59]Ho, KS, Ho KY. Randomized clinical trial comparing oral nifedipine with lateral anal sphincterotomy and tailored sphincterotomy in the treatment of chronic anal fissure [J]. Br J Surg,2005,92:403-408
[60]Cho DY. Controlled lateral sphincterotomy for chronic anal fissure[J]. Dis Colon Rectum,2005,48:1037-1041
[61]Rotholtz NA, Bun M, Mauri MV, et al. Long-term assessment of fecal incontinence after lateral internal sphincterotomy[J]. Tech Coloproctol 2005,9:115-118
[62]Madoff RD, Steele SR Anorectal manometry and anal fissure treatment:authors' reply[J]. Aliment Pharmacol Ther,2006,24:1652
[63]S. R. Mousavi,M. Sharifi, Zohreh Mehdikhah. A Comparison Between the Results of Fissurectomy and Lateral Internal Sphincterotomy in the Surgical Management of Chronic Anal Fissure[J].J Gastrointest Surg,2009,13:1279-1282
[64]Engel AF,Eijsbouts QA, Balk AG Fissurectomy and isosorbide dinitrate for chronic fissure in ano not responding to conservative treatment[J]. Br J Surg,2002,89:79-83
[65]Lindsey I, Cunningham C, Jones OM, et al. Fissurectomy-botul inum toxin:a novel sphinctersparing procedure for medically resistant chronic anal fissure [J]. Dis Colon Rectum,2004,47:1947-1952
[66]Renzi A, Izzo D, Di Sarno G. Clinical,Manometric,and Ultrasonographic Results of Pneumatic Balloon Dilatation vs Lateral Internal Sphincterotomy for Chronic Anal Fissure:A Prospective, Randomized, Controlled Trial[J]. Diseases of the Colon and Rectum.2008,51(1):121-127
[67]Boschetto S, Giovannone M, Tosnoni M, et al. Hydropneumatic anal dilatation in conservative treatment of chronic anal fissure:clinical outcomes and randomized comparison with topical nitroglycerin[J] Tech Coloproctol 2004; 8:89-93
[68]Tayfun Yucel,Dogan Gonullu,Mahmut Oncu. Comparison of controlled-intermittent anal dilatation and lateral internal sphincterotomy in the treatment of chronic anal fissures:A prospective, randomized study [J]. International Journal of Surgery,2009,7:228-231
[69]Giordano P,Gravante G,Grondona P, et al. Simple cutaneous advancement flap anoplasty for resistant chronic anal fissure:a prospective study[J]. World J Surg,2009,33(5):1058-1063
[70]Nyam DCNK, Wilson RG,Stewart KJ,et al. Island advancement flaps in the management of anal fissures[J].Br J Surg,2005,82 (3):326-328
[71]Kenefick NJ,Gee AS,Durdey P.Treatment of resistant anal fissure with advancement noplasty [J].Colorectal Dis,2002,4 (6):463-466
[72]Cross KL, Massey EJ, Fowler AL,et al. ACPGBI. The management of anal fissure: ACPGBI position statement[J]. Colorectal Dis,2008,10 (3):1-7
[73]Rigotti G,Marchi A,Galie M,et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant:a healing process mediated by adipose-derived adult stem cells [J]. Plast Reconstr Surg.2007; 119:1409-1422
[74]Lolli P, Malleo G, Rigotti G. Treatment of chronic anal fissures and associated stenosis by autologous adipose tissue transplant:a pilot study [J]. Dis Colon Rectum,2010,53:460-466
[1]Sandkuhler, Jurgen. Models and Mechanisms of Hyperalgesia and Allodynia [J]. Physiological Reviews.2009,89 (2):707-758
[2]Nakagawa T,Wakamatsu K,Zhang N,et al. Intrathecal administration of ATP produces long-lasting allodynia in rats:differential mechanisms in the phase of the induction and maintenance[J]. Neuroscience,2007,147:445-455
[3]张恒.SP与脊髓星形胶质细胞活化的关系及在大鼠慢性前列腺炎疼痛中的作用探讨[D].重庆.第三军医大学,2007
[4]Hansson E. Could chronic pain and spread of pain sensation be induced and maintained by glial activation? [J].Acta Physiol(Oxf),2006,187(12):321-327
[5]Hatashita S, Sekiguchi M, Kobayashi H, et al. Contra lateral neuropathic pain and neuropathology in dorsal root ganglion and spinal cord following hemilateral nerve injury in rats [J].Spine,2008,33 (12):1344-1351
[6]Fu D,Guo QL,YH Ai,et al.Glial Activation and segmental upregulation of inter leukin-1 β after surgical incision [J]. Neurochem Res,2006,31:333-340
[7]张文华,江剑平.白介素-1β在炎性痛中的作用及其机制[J].生命科学,2010,22(3)：291-295
[8]Scott DL,Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis[J].N Eng J Med 2006,355:704-712
[9]Zeilhofer HU.Prostanoids in nociception and pain [J]. Biochem Pharmacol, 2007,73:165-174
[10]韩彬彬,冯艺.环氧化酶-1在坐骨神经冷冻致神经病理性疼痛模型大鼠脊髓的表达.[J].中国康复理论与实践,2010,16(6)：528-531
[11]梁纯波,傅迪,郭曲练,等.脊髓肿瘤坏死因子-alpha(TNF-α)促进切割损伤导致的痛觉过敏[J].现代生物医学进展,2009,9(9)：1635-1637
[12]Taylor PC, Feldmann M. Anti-TNF biologic agents:still the therapy of choice for rheumatoid arthritis[J]. Nat Rev Rheumatol 2009; 5:578-582
[13]Cohen SP, Bogduk N,Dragovich A, et al. Randomized, double-blind, placebocontrolled,dose-response,and preclinical safety study of transforaminal epidural etanercept for the treatment of sciatica [J].Anesthesiology 2009,110:1116-1126
[14]Alvira CM,Abate A,Yang G, et al. Nuclear Factor-kB Activation in Neonatal Mouse Lung Protects against Lipopolysaccharideinduced Inflammation Am J Respir Crit Care Med.2007; 175:805-815
[15]Ndengele MM, Cuzzocrea S,Esposito E, et al. Cyclooxygenases land 2 contribute to peroxynitrite-mediated inflammatory pain hypersensitivity[J]. FASEB J.2008; 22:3154-3164
[16]Sophie Pezet, Stephen, B. McMahon. Neurotrophins:Mediators and Modulators of Pain[J]. Annual Review of Neuroscience.2006,29:507-538
[17]McMahon SB,Bennett DL,Bevan S. Inflammatory mediators and modulators [J]. Textbook of Pain,2006,1,49-72
[18]聂发传,王金保,苏东等.补体抑制剂对大鼠神经病理性疼痛模型的作用研究[J].中国疼痛医学杂志,2009,15(4)：240-242
[19]Sasaki A,Mabuchi T, Serizawa K, et al.Different roles of nitric oxide synthase-1 and-2 between herpetic and postherpetic allodynia in mice. Neuroscience,2007,150:459-466
[20]刘艳阳,胡兴国,曾因明.鞘内注射硫酸镁或/和吗啡对大鼠切口疼痛的影响[J].国际麻醉学与复苏杂志,2007,28(6)：497-501
[21]闫俊强,杨金升.N-甲基-D-天冬氨酸受体2B亚基与疼痛[J].医学综述,2008,14(8)：1153-1155
[22]林春,林国威,郑伟等.NMDA受体NR2B亚单位在慢性内脏痛觉敏化中的作用[J].中国药理学通报,2008,24(8)：1015-1018
[23]张晓琴,彭章龙,于布为.Non-NMDA受体在术后痛觉过敏中作用的研究进展[C]//方慧.2008年第七次华东六省一市麻醉学学术会议暨浙江省麻醉学术年会论文汇编(上册).杭州：杭州出版社,2008
[24]Lee SE, Kim JH. Involvement of substance P and calcitonin gene-related peptide in development and maintenance of neuropathic pain from spinal nerve injury model of rat[J].Neurosci Res,2007,58:245-249
[25]Li D, Ren Y, Xu X, et al. Sensi tization of primary afferent nociceptors induced by intradermal capsaicin involves the peripheral release of calcitonin gene-related peptide driven by dorsal root [J]. Pain,2008,9(12):1155-1168
[26]Greco R,Tassorelli C,Sandrini G,et al.Role of calcitonin gene-related peptide and substance P in different models of pain. Cephalalgia,2008,28 (2):114-126
[27]王英,鄢建勤.P2X3受体在疼痛机制中的作用[J].中国疼痛医学杂志,2009,15(3)：177-179
[28]Inoue K.Purinergic systems in microglia[J]. Cell Mol Life Sci,2008,65: 3074-3080
[29]李娜,崔可密,李为民.Y-氨基丁酸递质及其受体系统在痛觉中的作用[J].国际麻醉学与复苏杂志,2007,28(4)：342-245
[30]Graham ES,Ashton JC, GlassM. Cannabinoid Receptors:A briefhistory and "what's hot" [J].Front Biosci,2009,1:944-957
[31]Tohno M, Shimazu T, Aso H, et al. Molecular cloning and functional characterization of porcine MyD88 essential for TLR signaling [J].Cell Mol Immunol,2007,4:369-376
[32]Dib-Hajj SD,Cummins TR,Black JA,et al. Sodium channels in normal and pathological pain[J]. Annu Rev Neurosci,2010,33:325-347
[33]Cox JJ, Sheynin J,Shorer Z, et al. An SCN9A channelopathy causes congenital inability to experience pain[J]. Nature,2006,444:894-898
[34]张瑞,王清秀,郭慧琴.大鼠坐骨神经损伤性疼痛的行为观察和背根神经节中KvlmRNA的表达[J].现代医药卫生,2009,25(2)：165-166
[35]蒋兴凯,陈蕾,马冲.N-型钙通道及其阻断剂研究进展[J].国外医学药学分册报,2007,34(2)：93-98
[36]吴飞翔,俞卫锋.T型钙通道与疼痛[J].国际麻醉学与复苏杂志,2007,28(6)：565-567
[37]Perret D, Luo ZD. Targeting voltage-gated calcium channels for neuropathic pain management[J]. Neurotherapeutics,2009,6:679-692
[38]Ikeuchi M,Kolker SJ,Burnes LA,et al.Role of ASIC3 in the primary and secondary hyperalgesia produced by joint inflammation in mice[J]. Pain, 2008,137 (3):662-669
[39]JiRR, GereauRW, MalcangioM, et al. MAP kinase and pain.Brain Res Rev,2009,60: 135-148
[40]Roberts LA, Connor M. TRPV1 antagonists as a potential treatment for hyperalgesia; recent patents on CNS[J].Drug Dis,2006,1:65-76
[41]雷洪伊.脊髓ERK活化在瑞芬太尼引起术后痛觉过敏中的作用[D].广州.南方医科大学,2010
[42]卢国林.氟比洛芬醋预处理对急性疼痛大鼠抗伤害效应[D].福州,福建医科大学,2008
[43]龚琴,胡兴国,刘艳阳等.脊髓背角p38 MAPK活化在大鼠切口痛形成中的作用[J].中国疼痛医学杂志,2009,15(4)：226
[44]陈百红,陈雄刚,林财珠.氟比洛芬酯对手术致痛大鼠脊髓Fos蛋白表达的影响[J].现代生物医学进展,2009,9(15)：2824-2826
[1]彭俊付,刘勇,刘永刚.正交试验法优选广痛消中芍药苷的提取工艺[J].北京中医药大学学报,2011,34(4)：271-275
[2]彭俊付.广痛消泡沫气雾剂经直肠粘膜渗透率试验研究及其止痛与安全性临床观察[D].北京.北京中医药大学,2011
[3]彭俊付,赵宝明,张书信.RP-HPLC测定广痛消中芍药苷含量的方法[J].中国中药杂志,2011,36(23)：3268-3269
[4]吴振宇,吴广均,赵宝明.广痛消泡沫气雾剂的止痛解痉作用[J].中国中药杂志,2001,26(8)：559-561
[5]Cull-Candy S,Brickley S,FarrantM. NMDA receptor subunits:diversity, development and disease[J]. Curr Op Neurobiol,2001,11 (3):327
[6]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35
[7]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[8]王晓光,傅江南.常用中药药理研究与临床运用[M].北京：人民军医出版社,2006：220
[9]王红,田明,王淼,等.延胡索现代药理及临床研究进展[J].中医药学报,2010,38(6)：110
[10]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[11]酒淑玲.广痛消泡沫气雾剂促进混合痔术后创面愈合的临床研究[D].北京.北京中医药大学,2011
[12]陈美婉,陈听,潘昕,等.药用泡沫气雾剂的研究和应用概况[J].药学进展,2009,33(12)：549-551
[13]胡博.广痛消泡沫气雾剂剂型优势性研究[D].北京.北京中医药大学,2011
[1]Perry WB, Dykes SL, Buie WD. Practice Parameters for the Management of Anal Fissures (3rd Revision) [J].Dis Colon Rectum,2010,53:1110-1115
[2]G. Gagliardi,A. Pascariello, D. F. Altomare et al. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J]. Tech Coloproctol,2010,14:241-248
[3]Lysy J, Israeli E, Levy S, et al. Long-term results of "chemical sphincterotomy" for chronic anal fissure:a prospective study[J]. Dis Colon Rectum,2006,49: 858-864
[4]Nelson RL. Non surgical therapy for anal fissure. Cochrane Database [J] Syst Rev, 2006,4
[5]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35
[6]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[7]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[8]E. E. Collins,J. N. Lund. A review of chronic anal fissure management[J]. Tech Coloproctol,2007,11:209-223
[9]梅全喜.现代中药药理与临床应用手册[M].北京：中国中医药出版社,2008：790
[10]王晓光,傅江南.常用中药药理研究与临床运用[M].北京：人民军医出版社,2006：409
[11]Brodie BC. Lectures on diseases of the rectum, lecture Ⅲ:preternatureal contraction of the sphincter ani[J].Lond Med Gaz,1835,16:26-31
[12]Lin JK. Anal manometric studies in hemorrhoids and anal fissures [J]. Dis Colon Rectum,1989,32:839-842
[13]Khaikin M, Yebara S, Bashankaev B, et al. Topical Captopril Cream:A New Treatment for Anal Fissure?The First Human Study[J]. Dis Colon Rectum, 2007,50:747
[14]Gr iff in N,Acheson AG, Tung P, et al. Quality of life in patients with chronic anal fissure[J]. Colorectal Dis,2004,6:39-44
[15]Lund JN, Parson SL, Scholefield JH. Spasm of internal anal sphincter in anal fissure-cause or effect?[J]. Gastroenterology,1996,110:711
[16]Bailey HR,Beck DE, Billingham RP,et al.Fissure Study Group. A study to determine the nitroglycerin ointment dose and dosing interval that best promote the healing of chronic anal fissures[J]. Dis Colon Rectum,2002,45: 1192-1199
[17]Graziano A,Svidler Lopez L,Lencinas S, et al. Long-term results of topical nitroglycerin in the treatment of chronic anal fissures are disappointing [Jl.Tech Coloproctol,2001,5:143-147
[18]Jensen SL.Maintenance therapy with unprocessed bran in the prevention of acute anal fissure recurrence [J]. J R Soc Med,1987,80:296-298
[19]胡博.广痛消泡沫气雾剂剂型优势性研究[D].北京.北京中医药大学,2011
[1]E.E. Collins, J. N. Lund. A review of chronic anal fissure management [J]. Tech Coloproctol,2007,11:209-223
[2]陈奇.中药药理研究方法学[M].第一版.北京：人民卫生出版社,1993.1103
[3]G.Gagliardi,A.Pascariello, D. F. Altomare. Optimal treatment duration of glyceryl trinitrate for chronic anal fissure:results of a prospective randomized multicenter trial [J].Tech Coloproctol,2010,14:241-248
[4]赵雨千,陈绍宗,李强等.对Beitz大鼠后肢穿刺伤疼痛模型进行改良的实验研究[J].中国疼痛医学杂志,2010,10(21)：4022-4024
[5]Woolf CJ. Evidence for a central component of post-injury pain hypersensitivity[J]. Nature,1983,306:686-88
[6]Stebbing JF. Nitric oxide synthase neurones and neuromuscular behaviour of the anorectum[J]. Ann R Coll Surg Engl,1998,80:137-145
[7]Lund JN.Nitric oxide deficiency in the internal anal sphincter of patients with chronic anal fissure [J].Int J Colorectal Dis,2005
[8]L'Hopital F,Michelland 0, Lunaud B,et al. Constipation et hypertonie du sphincter interne de lanus:response sphincterienne a ladministration sub-linguale de 0.40 mg de Natispray [J]. Gastroenterol Clin Biol,1990,14:268
[9]赵宝明,史兆岐,景建中.广痛消泡沫气雾剂对肛门直肠疾病止痛作用的临床研究[J].中医杂志,1998,39(7)：412
[10]雒建瑞,王长淼,傅雷,等.芍药甙对家兔离体oddi括约肌肌环收缩活动的影响[J].大连医科大学学报,2009,31(6)：668-671
[11]Kassuya, C. A, J. Ferreira, R. F. Claudino, et al. Intraplantar PGE2 causes nociceptive behavior and mechanical allodynia:the role of prostanoid E receptors and protein kinases [J]. Br J Pharmacol,2007,150(6):727-737
[12]Turnbach, M. E, DS. Spraggins, and A.Randich. Spinal administration of prostaglan E (2) or prostaglandin F(2alpha) primarily produces mechanical hyperalgesia that is mediated by nociceptive specific spinal dorsal horn neurons [J]. Pain,2002,97(1-2):33-45
[13]Julius D, Basbaum Al.Molecular mechanisms of nociception [J].Nature,2001, 413:203-210
[14]Dolan S, Kelly JG,Huan M,et al.Transient up-regulation of spinal cyclooxygenase-2 and neuronal nitric oxide synthase following surgical inflammation[J]. Anesthesiology,2003,98:170-180
[15]赵宝明,张志谦,张书信等.广痛消泡沫气雾剂止血抗炎作用实验研究[J].中华中医药学刊,2011,29(10)：2164-2165
[16]C. Beinat, S. Banister,I. Moussa, et al.Insights into Structure-Activity Relationships and CNS Therapeutic Applications of NR2B Selective Antagonists[J]. Current Medicinal Chemistry,2010,17 (34):4166-4190
[17]林春,林国威,郑伟等.NMDA受体NR2B亚单位在慢性内脏痛觉敏化中的作用[J].中国药理学通报,2008,24(8)：1015-1018
[18]Blaise ML, Sowdhamini R, Rao MR, et al. Evolutionary trace analysis of ionotropic glutamate receptor sequences and modeling the interactions of agonists with different NMDA receptor subunits [J]. Mol Model,2004,10 (5-6): 305-316
[19]Ma QP, Hargreaves RJ. Localization of N-methyl-D-aspartate NR2B subunison Primary sensory neurons that give rise to small-caliber sciatic nerve fibers in rats [J]. Neuroscience,2000,101(3):699-707
[20]Nagy GG, Watanabe M, Fukaya M, et al. Synaptic distribution of the NR1, NR2A and NR2B subunits of the N-methyl-d-aspartate receptor in the rat lumbar spinal cord revealed with an antigen-unmasking technique[J]. Eur JNeurosci, 2004,20(12):3301-3312
[21]马江红.NR2B在糖尿病神经痛大鼠脊髓背角表达的变化[D].石家庄.北河北医科大学,2011
[22]Luque JM,Bleuel Z,Malherbe P, et al. Alternatively spliced isoforms of the N-methyl-D-aspartate receptor subunitl are differentially distributed within the rat spinal cord[J]. Neuroscience,1994,63 (90):629-635
[23]Lo Grasso P,Mckelvy J.Advances in Pain therapeutics[J]. Currop in Chem Biol,2003,7(4)452-456
[24]Tan PH, Yang LC, Shin HC, et al. Gene knockdown with intrathecal siRNA of NMDA receptor NR2B subunit reduces formalin-induced nociception in the rat [J].GeneTherapy,2005,12(1):59-66
[25]陈建平,田玉科,杨少兵.腹腔注射NR2B抗体对大鼠慢性神经病理性痛的镇痛效应[J].山西医科大学学报,2008,7：559-561
[26]Wang GM,Tian XB, Chen JP,et al. Prevention of neuropathic pain in an animal model of spare nerve injury following oral immunization with recombinant adenovirus serotype 5-mediated NR2B gene transfer [J]. GeneTher,2007, 14(24):1681-1687
[27]CaisO, Sed lacek M,Horak M, et al. Temperature dependence of NR1-NR2B NMDA receptor channels [J].Neuroscience,2008,151 (2):428-438
[28]张志谦,赵宝明,张书信等.广痛消泡沫气雾剂止痛促愈合的实验研究[J].中国中医药信息杂志,2012,19(3)：33-35